CIGB-247 vaccine breaks immunological tolerance to the vascular endothelial growth factor in mice, rats, rabbits and non-human primates, without disturbing physiologic angiogenic processes

CIGB-247 vaccine breaks immunological tolerance to the vascular endothelial growth factor in mice, rats, rabbits and non-human primates, without disturbing physiologic angiogenic processes

CIGB-247 is a novel cancer therapeutic vaccine that uses a mutated form of human vascular endothelial growth factor (VEGF) as antigen in combination with the oil-free adjuvant VSSP (very small sized proteoliposomes of Neisseria meningitidis outer membrane). The vaccine was designed to affect tumor n...

Full description

Bibliographic Details
Main Authors: Yanelys Morera, Mónica Bequet, Marta Ayala, Jorge V Gavilondo, Jorge Castro, Pedro Puente, Julio Ancízar, José Suarez, Javier Sanchez, Karelia Cosme, Dania Bacardí, Boris E Acevedo
Format: Article
Language:English
Published: Elfos Scientiae
Series:Biotecnología Aplicada
Subjects:
factor de crecimiento endotelial vascular
cáncer
vacuna
Online Access:http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522012000200008&lng=en&tlng=en

Internet

http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522012000200008&lng=en&tlng=en

Similar Items